Literature DB >> 31439434

Infiltrative Renal Masses: Clinical Significance and Fidelity of Documentation.

Hajime Tanaka1, Xiaobo Ding2, Yunlin Ye3, Yanbo Wang4, Rebecca A Campbell5, Molly E DeWitt-Foy5, Chalairat Suk-Ouichai6, Ryan D Ward7, Erick M Remer7, Jianbo Li8, Steven C Campbell9.   

Abstract

BACKGROUND: The prevalence of infiltrative renal masses (IRMs) and fidelity of documentation of infiltrative features remain unclear.
OBJECTIVE: To investigate the prevalence/significance of IRMs and assess whether infiltrative features were documented preoperatively. DESIGN, SETTING, AND PARTICIPANTS: A total of 522 patients with renal tumors managed with partial/radical nephrectomy (2012-2014) whose pathology demonstrated locally advanced and/or aggressive histology were analyzed. Preoperative computed tomography/magnetic resonance imaging was retrospectively/independently reviewed by two radiologists. IRMs were required to have a poorly defined interface with parenchyma and nonelliptical shape in one or more distinct/unequivocal areas. Infiltrative features were defined as extensive or focal. INTERVENTION: Partial/radical nephrectomy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cancer-specific mortality (CSM) was estimated using cumulative-incidence analysis. Significant and independent predictors of CSM were evaluated using Cox proportional hazard analysis. RESULTS AND LIMITATIONS: Median tumor size was 6.9cm; renal cell carcinomas (RCCs) predominated (92%). Image review confirmed 133 IRMs (25%), including 103 RCCs; 59 had sarcomatoid or poorly differentiated features. IRMs were larger and more often symptomatic compared than non-IRMs, and disseminated disease was also more common for IRMs (all p<0.001). Overall, 109 IRMs were imaged at our center; 42 were documented as IRMs in preoperative radiology reports, while infiltrative features were not documented in 67 (61%). Only four (6%) of these 67 were documented as infiltrative by the surgical team. Infiltrative features were more often focal in undocumented IRMs. On multivariable analysis, infiltrative features, disseminated disease, and non-RCC histology were independent predictors of CSM (hazard ratio or HR [95% confidence interval {CI}]=1.73 [1.21-2.47], 2.98 [2.10-4.23], and 2.79 [1.86-4.62], respectively). Among IRMs, extensive infiltrative features and disseminated disease were associated with CSM (HR [95% CI]=1.98 [1.27-3.07] and 2.35 [1.52-3.63], respectively), while documentation status failed to show an association. Excluding patients with disseminated disease or residual cancer after surgery, recurrence rates were 62% for IRMs versus 22% for non-IRMs (p<0.001), and there was again no significant difference between documented and undocumented IRMs (p=0.36). Limitations include a retrospective design.
CONCLUSIONS: Twenty-five percent of locally advanced/histologically aggressive renal tumors exhibited infiltrative features, although many were not documented as IRMs. Among this high-risk surgical population, infiltrative features were independent predictors of CSM, irrespective of whether they were documented or not. Our data suggest that infiltrative features should be assessed and documented routinely during evaluation of renal masses. PATIENT
SUMMARY: Infiltrative renal masses may be more common than previously appreciated, although many were not documented as infiltrative during preoperative evaluation. Our data suggest that infiltrative features have a strong impact on prognosis and should be assessed and documented routinely during radiologic and clinical evaluation of renal masses.
Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer-specific survival; Infiltrative renal mass; Locally advanced; Recurrence-free survival; Renal cell carcinoma

Year:  2019        PMID: 31439434     DOI: 10.1016/j.euo.2019.07.015

Source DB:  PubMed          Journal:  Eur Urol Oncol        ISSN: 2588-9311


  4 in total

1.  A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections.

Authors:  Paul Lloyd; Anne Hong; Marc A Furrer; Elaine W Y Lee; Harveer S Dev; Maurice H Coret; James M Adshead; Peter Baldwin; Richard Knight; Jonathan Shamash; Constantine Alifrangis; Sara Stoneham; Danish Mazhar; Han Wong; Anne Warren; Ben Tran; Nathan Lawrentschuk; David E Neal; Benjamin C Thomas
Journal:  World J Urol       Date:  2021-10-01       Impact factor: 4.226

2.  Outcomes of post-chemotherapy robot-assisted retroperitoneal lymph node dissection in testicular cancer: multi-institutional study.

Authors:  Haidar Abdul-Muhsin; Nicholas Rocco; Anojan Navaratnam; Michael Woods; James L'Esperance; Erik Castle; Sean Stroup
Journal:  World J Urol       Date:  2021-05-07       Impact factor: 4.226

3.  Indications, feasibility and outcome of robotic retroperitoneal lymph node dissection for metastatic testicular germ cell tumours.

Authors:  Carsten-Henning Ohlmann; Matthias Saar; Laura-Christin Pierchalla; Miran Zangana; Alena Bonaventura; Michael Stöckle; Stefan Siemer; Julia Heinzelbecker
Journal:  Sci Rep       Date:  2021-05-21       Impact factor: 4.379

4.  Clinical outcome of robot-assisted residual mass resection in metastatic nonseminomatous germ cell tumor.

Authors:  J L H Ruud Bosch; Joost M Blok; Henk G van der Poel; J Martijn Kerst; Axel Bex; Oscar R Brouwer; Simon Horenblas; Richard P Meijer
Journal:  World J Urol       Date:  2020-09-21       Impact factor: 4.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.